Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aladorian - ARMGO Pharma

Drug Profile

Aladorian - ARMGO Pharma

Alternative Names: ARM036; ARM036Na; S36; S36Na; S44121; S44121-1; S44121-2

Latest Information Update: 09 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; Servier
  • Class 2 ring heterocyclic compounds; Acids; Antiarrhythmics; Heart failure therapies; Small molecules; Thiazepines
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Ventricular tachycardia

Most Recent Events

  • 17 Aug 2017 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe (ARMGO Pharma pipeline, August 2017)
  • 10 Dec 2014 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe
  • 02 Feb 2012 Phase-II clinical trials in Ventricular tachycardia in Germany (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top